Vir Biotechnology Inc (VIR) stock saw a decline, ending the day at $12.1 which represents a decrease of $-0.38 or -3.04% from the prior close of $12.48. The stock opened at $12.69 and touched a low of ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...

Morgan Stanley upgraded shares of Vir Biotechnology (NASDAQ:VIR – Free Report) from an equal weight rating to an overweight rating in a report released on Thursday morning,Benzinga reports. They ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

Buckinghamshire residents who have been affected by lymphoma will come together for a supportive workshop next month. On ...

Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): ...

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

August Global Partners will assist Gene Solutions in enhancing the performance of their oncology solutions by providing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...